At the bedside: Profiling and treating patients with CXCR4‐expressing cancers
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
At the bedside: Profiling and treating patients with CXCR4‐expressing cancers
Authors
Keywords
-
Journal
JOURNAL OF LEUKOCYTE BIOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-10-22
DOI
10.1002/jlb.5bt1219-714r
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting FLT3 mutations in AML: review of current knowledge and evidence
- (2019) Naval Daver et al. LEUKEMIA
- Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer
- (2019) Wolfgang P. Fendler et al. JAMA Oncology
- A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
- (2018) David Martínez-Cuadrón et al. ANNALS OF HEMATOLOGY
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Theranostic radiopharmaceuticals: established agents in current use
- (2018) James R Ballinger BRITISH JOURNAL OF RADIOLOGY
- Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
- (2018) Gail J Roboz et al. HAEMATOLOGICA
- [68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia
- (2018) Marius E. Mayerhoefer et al. INVESTIGATIVE RADIOLOGY
- Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
- (2018) Sonia Pernas et al. LANCET ONCOLOGY
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics
- (2018) Stefan Habringer et al. Theranostics
- Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
- (2018) Gail J Roboz et al. HAEMATOLOGICA
- Extracellular Vesicles: A New Prospective in Crosstalk between Microenvironment and Stem Cells in Hematological Malignancies
- (2018) Ilaria Laurenzana et al. Stem Cells International
- Abstract 613: X4P-001, an orally bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma
- (2018) Robert H. Andtbacka et al. CANCER RESEARCH
- A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.
- (2018) Ulka N. Vaishampayan et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
- (2018) Prajwal Boddu et al. Frontiers in Oncology
- 1134PDA phase Ia/IIb trial of the CXCR4 inhibitor X4P-001 and nivolumab for advanced renal cell carcinoma (RCC) that is unresponsive to nivolumab monotherapy
- (2018) T K Choueiri et al. ANNALS OF ONCOLOGY
- Idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobinemia mimicking plasma cell myeloma
- (2018) Chih-Chieh Yen et al. BLOOD
- Theranostics Using Antibodies and Antibody-Related Therapeutics
- (2017) Kirsten L. Moek et al. JOURNAL OF NUCLEAR MEDICINE
- CXCR4 Ligands: The Next Big Hit?
- (2017) Annemiek M.E. Walenkamp et al. JOURNAL OF NUCLEAR MEDICINE
- Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial
- (2017) Darja Karpova et al. Journal of Translational Medicine
- A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer
- (2017) Ravi Salgia et al. LUNG CANCER
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Co
- (2017) Todd M. Cooper et al. PEDIATRIC BLOOD & CANCER
- [177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent
- (2017) Margret Schottelius et al. Theranostics
- CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma
- (2017) Constantin Lapa et al. Theranostics
- [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values
- (2017) Constantin Lapa et al. Theranostics
- Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach
- (2017) Rudolf A. Werner et al. Theranostics
- Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside
- (2017) Byung-Sik Cho et al. KOREAN JOURNAL OF INTERNAL MEDICINE
- Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia
- (2016) P. Herhaus et al. HAEMATOLOGICA
- First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers
- (2016) T. Vag et al. JOURNAL OF NUCLEAR MEDICINE
- 68Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma
- (2016) Constantin Lapa et al. Theranostics
- Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia
- (2016) P. Herhaus et al. HAEMATOLOGICA
- Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy
- (2015) B.-S. Cho et al. BLOOD
- In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma
- (2015) K. Philipp-Abbrederis et al. EMBO Molecular Medicine
- Molecular Imaging As a Tool for Drug Development and Trial Design
- (2015) Elisabeth G.E. de Vries et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease
- (2015) K. Herrmann et al. JOURNAL OF NUCLEAR MEDICINE
- Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
- (2015) Farhad Ravandi et al. LANCET ONCOLOGY
- Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway
- (2015) Manoj K. Kashyap et al. Oncotarget
- CXCR4 over-expression and survival in cancer: A system review and meta-analysis
- (2015) Hongli Zhao et al. Oncotarget
- Prospective Study of 68Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and First Application in Glioma Patients
- (2015) Zhe Wang et al. Theranostics
- Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging
- (2015) Hans Jürgen Wester et al. Theranostics
- Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition
- (2015) Edward Allan R. Sison et al. Oncotarget
- CXCR4WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplantMYD88L265P-directed survival signalling in Waldenström macroglobulinaemia cells
- (2014) Yang Cao et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
- (2014) M. D. Galsky et al. CLINICAL CANCER RESEARCH
- A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia
- (2013) G. Yang et al. BLOOD
- CXC Chemokine Receptor 4 Expression, CXC Chemokine Receptor 4 Activation, and Wild-Type Nucleophosmin Are Independently Associated With Unfavorable Prognosis in Patients With Acute Myeloid Leukemia
- (2013) Sergej Konoplev et al. Clinical Lymphoma Myeloma & Leukemia
- CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia
- (2013) Ye Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in Pediatric AML
- (2013) E. A. R. Sison et al. MOLECULAR CANCER RESEARCH
- The CXCR4 Antagonist AMD3465 Regulates Oncogenic Signaling and Invasiveness In Vitro and Prevents Breast Cancer Growth and Metastasis In Vivo
- (2013) Xiaoyang Ling et al. PLoS One
- A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
- (2012) G. L. Uy et al. BLOOD
- BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies
- (2012) M. R. Kuhne et al. CLINICAL CANCER RESEARCH
- A review on CXCR4/CXCL12 axis in oncology: No place to hide
- (2012) Urszula M. Domanska et al. EUROPEAN JOURNAL OF CANCER
- CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model
- (2012) Y Zhang et al. Cell Death & Disease
- Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting
- (2011) Marina Y. Konopleva et al. JOURNAL OF CLINICAL ONCOLOGY
- Advances in the assessment and control of the effector functions of therapeutic antibodies
- (2011) Xu-Rong Jiang et al. NATURE REVIEWS DRUG DISCOVERY
- Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis
- (2010) D. H. McDermott et al. BLOOD
- CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth
- (2010) Katia Beider et al. EXPERIMENTAL HEMATOLOGY
- The CXCR4/SDF-1 Chemokine Receptor Axis: A New Target Therapeutic for Non-small Cell Lung Cancer
- (2010) Shannon Otsuka et al. Journal of Thoracic Oncology
- FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous Transplantation
- (2010) Michael Brave et al. ONCOLOGY
- Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
- (2008) S. M. Devine et al. BLOOD
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
- (2008) Z. Zeng et al. BLOOD
- Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells
- (2008) Angela Colmone et al. SCIENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started